Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

36%

4 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

6(60.0%)

Phase 3

4(40.0%)

10Total

Phase 2(6)

Phase 3(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT07227103Phase 2Not Yet Recruiting

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression

Role: lead

NCT04843761Phase 3Completed

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

Role: collaborator

NCT06729606Phase 3Completed

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Role: collaborator

NCT03395392Phase 2Completed

NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

Role: lead

NCT04990466Phase 2Withdrawn

Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.

Role: lead

NCT03396601Phase 3Unknown

NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression

Role: lead

NCT03396068Phase 3Unknown

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

Role: lead

NCT06128213Phase 2Unknown

NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis

Role: lead

NCT05779267Unknown

NRX-101 Expanded Access

Role: lead

NCT03402152Phase 2Completed

NRX101 Glx Biomarker Validation Study

Role: lead

NCT02974010Phase 2Completed

Sequential Therapy for the Treatment of Severe Bipolar Depression.

Role: lead

All 11 trials loaded